191 related articles for article (PubMed ID: 32820015)
21. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias.
Lawrence HJ; Rozenfeld S; Cruz C; Matsukuma K; Kwong A; Kömüves L; Buchberg AM; Largman C
Leukemia; 1999 Dec; 13(12):1993-9. PubMed ID: 10602420
[TBL] [Abstract][Full Text] [Related]
22. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.
Röllig C; Kramer M; Gabrecht M; Hänel M; Herbst R; Kaiser U; Schmitz N; Kullmer J; Fetscher S; Link H; Mantovani-Löffler L; Krümpelmann U; Neuhaus T; Heits F; Einsele H; Ritter B; Bornhäuser M; Schetelig J; Thiede C; Mohr B; Schaich M; Platzbecker U; Schäfer-Eckart K; Krämer A; Berdel WE; Serve H; Ehninger G; Schuler US;
Ann Oncol; 2018 Apr; 29(4):973-978. PubMed ID: 29390048
[TBL] [Abstract][Full Text] [Related]
23. NUP98-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid-committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression.
Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Vargas MT; García-Lozano JR; Falantes JF; Prats-Martín C; Bernal R; Pérez-Simón JA
Int J Lab Hematol; 2016 Feb; 38(1):64-71. PubMed ID: 26418229
[TBL] [Abstract][Full Text] [Related]
24. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
Barr PM; Saylors GB; Spurgeon SE; Cheson BD; Greenwald DR; O'Brien SM; Liem AK; Mclntyre RE; Joshi A; Abella-Dominicis E; Hawkins MJ; Reddy A; Di Paolo J; Lee H; He J; Hu J; Dreiling LK; Friedberg JW
Blood; 2016 May; 127(20):2411-5. PubMed ID: 26968534
[TBL] [Abstract][Full Text] [Related]
25. Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.
Krug U; Koschmieder A; Schwammbach D; Gerss J; Tidow N; Steffen B; Bug G; Brandts CH; Schaich M; Röllig C; Thiede C; Noppeney R; Stelljes M; Büchner T; Koschmieder S; Dührsen U; Serve H; Ehninger G; Berdel WE; Müller-Tidow C
PLoS One; 2012; 7(12):e52695. PubMed ID: 23300745
[TBL] [Abstract][Full Text] [Related]
26. Flt3 is dispensable to the Hoxa9/Meis1 leukemogenic cooperation.
Morgado E; Albouhair S; Lavau C
Blood; 2007 May; 109(9):4020-2. PubMed ID: 17202314
[TBL] [Abstract][Full Text] [Related]
27. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
[TBL] [Abstract][Full Text] [Related]
28. Conditionally immortalised leukaemia initiating cells co-expressing Hoxa9/Meis1 demonstrate microenvironmental adaptation properties ex vivo while maintaining myelomonocytic memory.
Stahlhut M; Ha TC; Takmakova E; Morgan MA; Schwarzer A; Schaudien D; Eder M; Schambach A; Kustikova OS
Sci Rep; 2021 Mar; 11(1):5294. PubMed ID: 33674652
[TBL] [Abstract][Full Text] [Related]
29. Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
Awan FT; Thirman MJ; Patel-Donnelly D; Assouline S; Rao AV; Ye W; Hill B; Sharman JP
Leuk Lymphoma; 2019 Aug; 60(8):1972-1977. PubMed ID: 30633573
[TBL] [Abstract][Full Text] [Related]
30. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
31. The Historical Relationship Between Meis1 and Leukemia.
Meriç N; Kocabaş F
Adv Exp Med Biol; 2022; 1387():127-144. PubMed ID: 35304708
[TBL] [Abstract][Full Text] [Related]
32. C/EBPα is an essential collaborator in Hoxa9/Meis1-mediated leukemogenesis.
Collins C; Wang J; Miao H; Bronstein J; Nawer H; Xu T; Figueroa M; Muntean AG; Hess JL
Proc Natl Acad Sci U S A; 2014 Jul; 111(27):9899-904. PubMed ID: 24958854
[TBL] [Abstract][Full Text] [Related]
33. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Gore L; Triche TJ; Farrar JE; Wai D; Legendre C; Gooden GC; Liang WS; Carpten J; Lee D; Alvaro F; Macy ME; Arndt C; Barnette P; Cooper T; Martin L; Narendran A; Pollard J; Meshinchi S; Boklan J; Arceci RJ; Salhia B
Clin Epigenetics; 2017; 9():108. PubMed ID: 29034009
[TBL] [Abstract][Full Text] [Related]
34. Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia.
Bhayadia R; Krowiorz K; Haetscher N; Jammal R; Emmrich S; Obulkasim A; Fiedler J; Schwarzer A; Rouhi A; Heuser M; Wingert S; Bothur S; Döhner K; Mätzig T; Ng M; Reinhardt D; Döhner H; Zwaan CM; van den Heuvel Eibrink M; Heckl D; Fornerod M; Thum T; Humphries RK; Rieger MA; Kuchenbauer F; Klusmann JH
J Clin Oncol; 2018 Apr; 36(10):1007-1016. PubMed ID: 29432078
[TBL] [Abstract][Full Text] [Related]
35. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
Wiernik PH; Banks PL; Case DC; Arlin ZA; Periman PO; Todd MB; Ritch PS; Enck RE; Weitberg AB
Blood; 1992 Jan; 79(2):313-9. PubMed ID: 1730080
[TBL] [Abstract][Full Text] [Related]
36. Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes.
Wang GG; Pasillas MP; Kamps MP
Mol Cell Biol; 2006 May; 26(10):3902-16. PubMed ID: 16648484
[TBL] [Abstract][Full Text] [Related]
37. Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus.
Wang GG; Pasillas MP; Kamps MP
Blood; 2005 Jul; 106(1):254-64. PubMed ID: 15755900
[TBL] [Abstract][Full Text] [Related]
38. Meis1 supports leukemogenesis through stimulation of ribosomal biogenesis and Myc.
Garcia-Cuellar MP; Prinz A; Slany RK
Haematologica; 2022 Nov; 107(11):2601-2616. PubMed ID: 35546301
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality.
Rozovskaia T; Feinstein E; Mor O; Foa R; Blechman J; Nakamura T; Croce CM; Cimino G; Canaani E
Oncogene; 2001 Feb; 20(7):874-8. PubMed ID: 11314021
[TBL] [Abstract][Full Text] [Related]
40. p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.
Zhang J; Seet CS; Sun C; Li J; You D; Volk A; Breslin P; Li X; Wei W; Qian Z; Zeleznik-Le NJ; Zhang Z; Zhang J
Mol Oncol; 2013 Dec; 7(6):1069-82. PubMed ID: 23988911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
